36. 表皮水疱症 Disease details / Clinical trials / Drug dev / DR info

ABH001
   Shire Regenerative Medicine, Inc.
      2013   -   EUCTR2012-001815-21-PT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-ES   Australia;Austria;Germany;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-DE   Australia;Austria;Germany;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-AT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
      2012   Phase 3   NCT01749306   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
AC-203
   Castle Creek Pharmaceuticals, LLC
      2017   Phase 2   EUCTR2016-004427-24-NL   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-GB   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-DE   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-AT   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      -   Phase 2   EUCTR2016-004427-24-FR   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States
   TWi Biotechnology, Inc.
      2024   Phase 2/Phase 3   NCT06073132   Australia;Austria;Belgium;France;Greece;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Spain;Taiwan;United Arab Emirates;United Kingdom;United States
      2018   Phase 2   NCT03468322   Taiwan
Agle 102
   Aegle Therapeutics
      2024   Phase 1/Phase 2   NCT04173650   United States
Alemtuzumab
   Columbia University
      2009   Early Phase 1   NCT00881556   United States
Allantoin
   Scioderm INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-002288-14-BE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, An Amicus Therapeutics Company
      2016   Phase 3   EUCTR2014-002288-14-LT   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002288-14-PL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002288-14-DE   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-NL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-GB   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC
      2016   Phase 3   EUCTR2014-005679-96-ES   Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-NL   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-GB   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-005679-96-LT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-DE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-005679-96-PL   Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC.
      2016   Phase 3   EUCTR2014-002288-14-ES   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-IT   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
Allantoina
   SCIODERM, INC
      -   Phase 3   EUCTR2014-005679-96-IT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
ALLO-APZ2-EB
   RHEACELL GmbH & Co. KG
      2019   Phase 1/Phase 2   NCT03529877   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 1   EUCTR2018-001009-98-IT   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-FR   Austria;France;Germany;United Kingdom;United States
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-DE   Austria;France;Germany;Italy;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-GB   Austria;France;Germany;Italy;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-AT   Austria;France;Germany;Italy;United Kingdom;United States
ALLO-APZ2-OTS
   RHEACELL GmbH & Co. KG
      2023   Phase 3   NCT05838092   United States
      2023   Phase 3   NCT05464381   Austria
ALLO-ASC-DFU
   Anterogen Co., Ltd.
      2017   -   NCT03183934   Korea, Republic of
ALLO-ASC-sheet
   Anterogen Co., Ltd.
      2023   Phase 2   NCT05157958   United States
Allogeneic adipose tissue-derived MSC
   Masarykova univerzita
      2021   Phase 1;Phase 2   EUCTR2020-002936-55-CZ   Czech Republic
Allogeneic mesenchymal stromal cells
   King's College London
      2015   Phase 1;Phase 2   EUCTR2014-004500-30-GB   United Kingdom
Allogeneic SKIN-derived ABCB5-positive mesenchymal stem cells
   RHEACELL GmbH & Co. KG
      2019   Phase 1   EUCTR2018-001009-98-IT   Austria;France;Germany;Italy;United Kingdom;United States
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-FR   Austria;France;Germany;United Kingdom;United States
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-DE   Austria;France;Germany;Italy;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-GB   Austria;France;Germany;Italy;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-AT   Austria;France;Germany;Italy;United Kingdom;United States
Allogenic mesenchymal stromal cells
   King's College London
      2012   Phase 1;Phase 2   EUCTR2012-001394-87-GB   United Kingdom
Alwextin cream
   Northwestern University
      2009   Phase 2   NCT00825565   United States
ANTI-thymocyte globulin
   Masonic Cancer Center, University of Minnesota
      2010   Phase 1/Phase 2   NCT01033552   United States
Apremilast treatment
   Centre Hospitalier Universitaire de Nice
      2024   Phase 2   NCT06509984   France
B-VEC
   Chen Hubert
      2023   Phase 3   JPRN-jRCT2053230075   Japan;United States
   Krystal Biotech, Inc.
      2021   Phase 3   NCT04917874   United States
Bioopa dressing
   Medical University of Warsaw
      2020   Phase 1;Phase 2   EUCTR2018-003890-91-PL   Poland
Birch bark extract
   Amryt Research Limited
      2018   Phase 3   EUCTR2016-002066-32-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-BE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-IT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-IE   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-ES   Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      -   Phase 3   EUCTR2016-002066-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      -   Phase 3   EUCTR2016-002066-32-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States
Bone marrow infusion
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
Bone marrow or umbilical cord blood (UCG) stem cell transplantation
   Masonic Cancer Center, University of Minnesota
      2010   Phase 1/Phase 2   NCT01033552   United States
Botox
   Toulouse Hospital
      2017   Phase 2   EUCTR2017-002332-16-FR   France
Botulinic toxin
   University Hospital, Toulouse
      2018   Phase 2/Phase 3   NCT03453632   France
Busilvex
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands
Busulfan
   Columbia University
      2009   Early Phase 1   NCT00881556   United States
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
      2007   -   NCT00478244   United States
Bvec
   Stanford University
      2025   Phase 2   NCT06731933   Italy;United States
Cacipliq20
   Organ, Tissue, Regeneration, Repair and Replacement
      2024   -   NCT06007235   France
Calcipotriol
   Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg
      2016   Phase 2   EUCTR2016-001967-35-AT   Austria
Cannabidiol
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 2   NCT05651607   France
   Elena Pope
      2020   Phase 2/Phase 3   NCT04613102   Canada
   University Medical Center Groningen
      -   Phase 2   EUCTR2021-000103-20-NL   Netherlands
Cannabinol
   InMed Pharmaceuticals Inc.
      2022   Phase 2   EUCTR2021-000214-42-ES   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-IT   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-GR   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-AT   Austria;France;Germany;Greece;Israel;Italy;Serbia
      -   Phase 2   EUCTR2021-000214-42-FR   Austria;France;Germany;Greece;Israel;Italy;Serbia
      -   Phase 2   EUCTR2021-000214-42-DE   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
CBD
   University Medical Center Groningen
      -   Phase 2   EUCTR2021-000103-20-NL   Netherlands
CBN
   InMed Pharmaceuticals Inc.
      2022   Phase 2   EUCTR2021-000214-42-ES   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-IT   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-GR   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-AT   Austria;France;Germany;Greece;Israel;Italy;Serbia
      -   Phase 2   EUCTR2021-000214-42-FR   Austria;France;Germany;Greece;Israel;Italy;Serbia
      -   Phase 2   EUCTR2021-000214-42-DE   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
CCP-020
   Castle Creek Pharmaceuticals, LLC
      2018   Phase 1   EUCTR2018-000439-29-GB   France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-NL   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-GB   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-FR   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-DE   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-AT   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-NL   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-GB   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-DE   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-AT   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      -   Phase 2   EUCTR2016-004427-24-FR   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States
      -   Phase 1   EUCTR2018-000439-29-NL   France;Germany;Netherlands;United Kingdom;United States
Cell transplantation
   Royan Institute
      2010   Phase 1   NCT01908088   Iran, Islamic Republic of
COL7a1-SIN retroviral vector engineered autologous tissue-engineered skin
   Institut National de la Santé Et de la Recherche Médicale, France
      2020   Phase 1/Phase 2   NCT04186650   France
Control GEL
   Amryt Research Limited
      2017   Phase 3   NCT03068780   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States
Control wound treatment
   Shire Regenerative Medicine, Inc.
      2012   Phase 3   NCT01749306   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
Cultured allogeneic fibroblasts
   Intercytex Ltd
      2011   Phase 2   EUCTR2010-023121-38-GB   United Kingdom
CX501
   CELLERIX, S.A.
      2006   Phase 2   EUCTR2005-002329-30-ES   Spain
   Tigenix S.A.U.
      2006   Phase 2   NCT00987142   Spain
Cyclophosphamide
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
      2010   Phase 1/Phase 2   NCT01033552   United States
      2007   -   NCT00478244   United States
Cyclosporine A
   Masonic Cancer Center, University of Minnesota
      2010   Phase 1/Phase 2   NCT01033552   United States
Células madre mesenquimales haploidénticas derivadas DE Médula óSEA
   Fundación para la Investigación Biomédica Hospital Universitario La Paz
      2017   Phase 1   EUCTR2017-000606-37-ES   Spain
D-FI
   Castle Creek Biosciences, LLC.
      2025   Phase 3   NCT06892639   United States
Delta-9-tetrahydrocannabinol
   University Medical Center Groningen
      -   Phase 2   EUCTR2021-000103-20-NL   Netherlands
Deucravacitinib
   Centre Hospitalier Universitaire de Nice
      2023   Phase 2   NCT06136403   France
Diacerein
   Castle Creek Pharmaceuticals, LLC
      2018   Phase 1   EUCTR2018-000439-29-GB   France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-NL   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-GB   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-FR   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-DE   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003757-41-AT   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-NL   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-GB   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-DE   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004427-24-AT   Australia;Austria;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States
      -   Phase 1   EUCTR2018-000439-29-NL   France;Germany;Netherlands;United Kingdom;United States
      -   Phase 2   EUCTR2016-004427-24-FR   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States
   EB House Austria
      2013   Phase 3   EUCTR2013-002034-21-AT   Austria
Diacerein 1% ointment
   Castle Creek Pharmaceuticals, LLC
      2018   Phase 1   NCT03472287   France;Netherlands;United Kingdom;United States
      2017   Phase 2   NCT03389308   United States
      2017   Phase 2   NCT03154333   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States
Diacerin cream
   Tel-Aviv Sourasky Medical Center
      2015   Phase 2   NCT02470689   -
Donor mesenchymal stem cell infusions
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
Dysport
   Sophiahemmet
      2009   Phase 2   EUCTR2009-010763-17-SE   Sweden
   Uppsala University
      2009   Phase 2   NCT00936533   Sweden
EB-101
   Abeona Therapeutics, Inc
      2021   -   NCT05708677   United States
      2020   Phase 3   NCT04227106   United States
   Jean Yuh Tang
      2018   Phase 3   NCT03632265   -
EB-101 surgical application OF rdeb wounds
   Abeona Therapeutics, Inc
      2023   Phase 3   NCT05725018   United States
Episalvan GEL
   Amryt Research Limited
      2018   Phase 3   EUCTR2016-002066-32-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-BE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-IT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-IE   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-ES   Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      -   Phase 3   EUCTR2016-002066-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      -   Phase 3   EUCTR2016-002066-32-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States
Erythrocine oral
   CHU de NICE
      -   Phase 2   EUCTR2010-024428-10-FR   France
Erythromycine
   CHU de NICE
      -   Phase 2   EUCTR2010-024428-10-FR   France
EX-VIVO-expanded autologous human keratinocytes containing epidermal stem cells transduced with A LAMB3-encoding retroviral vector
   Holostem Terapie Avanzate s.r.l.
      -   Phase 1;Phase 2   EUCTR2022-001780-27-DE   Germany
FCX-007
   Castle Creek Biosciences, LLC.
      2016   Phase 1/Phase 2   NCT02810951   United States
FCX-007 (dabocemagene autoficel
   Castle Creek Biosciences, LLC.
      2020   Phase 3   NCT04213261   United States
Filsuvez
   Amryt Pharma
      2024   -   NCT06423573   France
Fludarabine
   Columbia University
      2009   Early Phase 1   NCT00881556   United States
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
      2010   Phase 1/Phase 2   NCT01033552   United States
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands
Fludarabine phosphate
   Masonic Cancer Center, University of Minnesota
      2007   -   NCT00478244   United States
GENE-modified autologous fibroblasts
   King's College London
      2015   Phase 1   NCT02493816   United Kingdom
Gentamicin
   University of Southern California
      2018   Phase 1/Phase 2   NCT03392909   United States
      2016   Phase 1/Phase 2   NCT02698735   -
Gentamicin sulfate
   Oslo University Hospital
      2020   Phase 1/Phase 2   NCT04644627   Norway
   University of Southern California
      2018   Phase 1/Phase 2   NCT03526159   United States
      2017   Phase 1/Phase 2   NCT03012191   United States
Gentamicin sulfate 0.1% ointment
   Oslo University Hospital
      2020   Phase 2   EUCTR2020-002337-15-NO   Norway
Gentamicin sulfate, injectable
   University of Southern California
      2019   Phase 1/Phase 2   NCT04140786   United States
Granulocyte colony stimulating factor
   Vanderbilt University Medical Center
      2012   Phase 2   NCT01538862   United States
Growth hormone level and insulin like growth factor 1
   Cairo University
      2022   -   NCT05390073   -
Hematopoietic bone marrow transplantation
   Masonic Cancer Center, University of Minnesota
      2007   -   NCT00478244   United States
Hologene 5
   HOLOSTEM TERAPIE AVANZATE S.R.L.
      2021   Phase 2;Phase 3   EUCTR2018-000261-36-IT   France;Germany;Italy
   Holostem Terapie Avanzate s.r.l.
      2021   Phase 2;Phase 3   EUCTR2018-000261-36-FR   France;Italy
      -   Phase 1;Phase 2   EUCTR2022-001780-27-DE   Germany
Hologene17
   Holostem Terapie Avanzate s.r.l.
      2017   Phase 1;Phase 2   EUCTR2016-000095-17-AT   Austria
Hologene7
   Holostem Terapie Avanzate s.r.l.
      2016   Phase 1;Phase 2   EUCTR2015-004592-74-AT   Austria
HP802-247
   Healthpoint
      2012   Phase 2   NCT01528306   United States
Human allogeneic adipose tissue-derived mesenchymal stem cells expanded
   Masarykova univerzita
      2021   Phase 1;Phase 2   EUCTR2020-002936-55-CZ   Czech Republic
Human allogeneic WJ-mscs
   Medical University of Warsaw
      2020   Phase 1;Phase 2   EUCTR2018-003890-91-PL   Poland
Human dermal fibroblasts cultured ON A bioresorbable polyglactin mesh
   Shire Regenerative Medicine, Inc.
      2013   -   EUCTR2012-001815-21-PT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-ES   Australia;Austria;Germany;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-DE   Australia;Austria;Germany;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-AT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
Human fibroblast-derived dermal substitute, dermagraft
   Shire Regenerative Medicine, Inc.
      2013   -   EUCTR2012-001815-21-PT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-ES   Australia;Austria;Germany;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-DE   Australia;Austria;Germany;Portugal;Spain;United States
      2013   -   EUCTR2012-001815-21-AT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States
Human umbilical cord blood-derived mesenchymal stem cells
   Gangnam Severance Hospital
      2016   Phase 1/Phase 2   NCT04520022   Korea, Republic of
ICX-RHY-013
   Intercytex Ltd
      2011   Phase 2   EUCTR2010-023121-38-GB   United Kingdom
Immunoglobulin G
   M. Peter Marinkovich
      2025   Phase 1/Phase 2   NCT06834035   United States
Infectogenta
   Oslo University Hospital
      2020   Phase 2   EUCTR2020-002337-15-NO   Norway
INM-755
   InMed Pharmaceuticals Inc.
      2022   Phase 2   EUCTR2021-000214-42-ES   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-IT   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-GR   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
      2021   Phase 2   EUCTR2021-000214-42-AT   Austria;France;Germany;Greece;Israel;Italy;Serbia
      -   Phase 2   EUCTR2021-000214-42-FR   Austria;France;Germany;Greece;Israel;Italy;Serbia
      -   Phase 2   EUCTR2021-000214-42-DE   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain
INM-755 (cannabinol) cream
   InMed Pharmaceuticals Inc.
      2021   Phase 2   NCT04908215   Austria;France;Germany;Greece;Israel;Italy
Isotretinoin
   University of North Carolina
      2000   Phase 1   NCT00014729   -
Ixekizumab
   CHU NICE
      2020   Phase 2   EUCTR2020-001542-19-FR   France
Jojoba OIL with broccoli sprout extract
   Johns Hopkins University
      2015   Phase 1   NCT02592954   United States
Lorazepam
   Columbia University
      2009   Early Phase 1   NCT00881556   United States
Losartan hexal
   Medical Center - University of Freiburg
      2017   Phase 2   EUCTR2015-003670-32-AT   Austria;Germany
      -   Phase 2   EUCTR2015-003670-32-DE   Austria;Germany
Losartan potassium
   Medical Center - University of Freiburg
      2017   Phase 2   EUCTR2015-003670-32-AT   Austria;Germany
      -   Phase 2   EUCTR2015-003670-32-DE   Austria;Germany
Lzrse-COL7a1 engineered autologous epidermal sheets
   Stanford University
      2010   Phase 1/Phase 2   NCT01263379   United States
Mesenchymal stem cell transplantation
   Masonic Cancer Center, University of Minnesota
      2010   Phase 1/Phase 2   NCT01033552   United States
Mesenchymal stem cells extracted from bone marrow
   Fundación para la Investigación Biomédica Hospital Universitario La Paz
      2017   Phase 1   EUCTR2017-000606-37-ES   Spain
Mesenchymal stromal cells
   Ishin Pharmaceutical Co. Ltd.
      2017   Phase 1,2   JPRN-UMIN000028366   Japan
   King's College London
      2015   Phase 1/Phase 2   NCT02323789   United Kingdom
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands
Methoxsalen
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004359   -
Methylcellulose
   Chen Hubert
      2023   Phase 3   JPRN-jRCT2053230075   Japan;United States
Morphine sulphate IN intrasite GEL
   Institute of Child Health
      2005   Phase 4   NCT00231517   United Kingdom
Mycophenolate mofetil
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
      2010   Phase 1/Phase 2   NCT01033552   United States
Normal saline
   Phoenix Tissue Repair, Inc.
      2019   Phase 1/Phase 2   NCT03752905   United States
NOT YET assigned
   Holostem Terapie Avanzate s.r.l.
      -   Phase 1;Phase 2   EUCTR2022-001780-27-DE   Germany
Occlusive NON adherent dressing
   Tigenix S.A.U.
      2006   Phase 2   NCT00987142   Spain
Oleogel-S10
   Amryt Research Limited
      2018   Phase 3   EUCTR2016-002066-32-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2018   Phase 3   EUCTR2016-002066-32-BE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2017   Phase 3   NCT03068780   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-IT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-IE   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
      2017   Phase 3   EUCTR2016-002066-32-ES   Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002066-32-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      -   Phase 3   EUCTR2016-002066-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom
      -   Phase 3   EUCTR2016-002066-32-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States
   Chiesi Farmaceutici S.p.A.
      2025   Phase 3   NCT06917690   Japan
ON 01910.NA
   Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria
      2017   Phase 2   EUCTR2016-003832-19-AT   Austria
Oral erythromycin
   Centre Hospitalier Universitaire de Nice
      2011   Phase 3   NCT01340235   France
Palifermin
   Columbia University
      2009   Early Phase 1   NCT00881556   United States
Polyphenon E
   CHU de NICE
      2010   -   EUCTR2009-012750-21-FR   France
   Centre Hospitalier Universitaire de Nice
      2010   Phase 2   NCT00951964   France
Pregabalin
   The Hospital for Sick Children
      2019   Phase 3   NCT03928093   Canada
Psorcutan-ointment
   Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg
      2016   Phase 2   EUCTR2016-001967-35-AT   Austria
PTR-01
   Phoenix Tissue Repair, Inc.
      2021   Phase 2   NCT05143190   United States
      2020   Phase 2   NCT04599881   United States
      2019   Phase 1/Phase 2   NCT03752905   United States
PTW-002 10 MG/G GEL
   Phoenicis Therapeutics
      2023   Phase 1/Phase 2   NCT05529134   United States
QR-313
   Phoenicis Therapeutics
      2018   Phase 1/Phase 2   NCT03605069   France;Spain;United States
QR-313 GEL FOR topical (cutaneous) administration
   ProQR Therapeutics
      -   Phase 1;Phase 2   EUCTR2017-004806-17-FR   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
   ProQR Theraputics
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-ES   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
   Wings Therapeutics Inc.
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-GB   Czech Republic;France;Germany;Spain;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-DE   Czech Republic;France;Germany;Spain;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2017-004806-17-CZ   Czech Republic;France;Germany;Spain;United Kingdom;United States
Quality-OF-life assessment
   Thomas Jefferson University
      2021   Early Phase 1   NCT04177498   United States
Redasemtide
   SHIONOGI & CO., LTD.
      2019   Phase 2   JPRN-jRCT2080224722   Japan
Rege PRO dressing
   Egyptian Atomic Energy Authority
      2017   -   NCT03942250   Egypt
Rigosertib
   Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria
      2017   Phase 2   EUCTR2016-003832-19-AT   Austria
Rigosertib oral capsules / rigosertib intravenous
   Prof. Johann Bauer
      2021   Phase 1/Phase 2   NCT03786237   Austria
Rigosertib sodium
   Thomas Jefferson University
      2021   Early Phase 1   NCT04177498   United States
Rituximab
   Research group of rare intractable dermatologial disorder
      2010   Phase 2   JPRN-UMIN000004428   Japan
Ropivacaine
   Assistance Publique - Hôpitaux de Paris
      2017   -   NCT03730584   France
Sass
   CHU de Quebec-Universite Laval
      2019   Early Phase 1   NCT04171661   Canada
SD-101
   SCIODERM, INC
      -   Phase 3   EUCTR2014-005679-96-IT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-002288-14-BE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, An Amicus Therapeutics Company
      2016   Phase 3   EUCTR2014-002288-14-LT   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002288-14-PL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002288-14-DE   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-NL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-GB   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC
      2016   Phase 3   EUCTR2014-005679-96-ES   Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-NL   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-GB   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-005679-96-LT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-DE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-005679-96-PL   Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC.
      2016   Phase 3   EUCTR2014-002288-14-ES   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-IT   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
   Scioderm, Inc.
      2014   Phase 2   NCT02090283   United States
      2014   Phase 2   NCT02014376   United States
SD-101-6.0 cream
   Scioderm, Inc.
      2015   Phase 3   NCT02670330   Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   NCT02384460   Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States
Sericare
   Birken AG
      2010   Phase 2   NCT01294241   Germany
   Birken GmbH
      2010   -   EUCTR2010-019945-24-DE   Germany
Serlopitant tablet
   Stanford University
      2019   Phase 2   NCT03836001   United States
Simplecare
   EB House Austria
      2013   Phase 3   EUCTR2013-002034-21-AT   Austria
SIN LV mediated EX vivo transduced autologous fibroblasts expressing codon-optimised COL7a1
   King's College London
      2016   Phase 1   EUCTR2014-004884-19-GB   United Kingdom
SIN RV-mediated COL7a1 corrected autologous skin equivalent
   INSERM
      2019   Phase 1;Phase 2   EUCTR2016-002790-35-FR   France
Sirolimus
   Premier Specialists, Australia
      2016   Phase 2   NCT03016715   Australia
   Stanford University
      2016   Phase 2   NCT02960997   United States
Tacrolimus
   Columbia University
      2009   Early Phase 1   NCT00881556   United States
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
Taltz 80MG
   CHU NICE
      2020   Phase 2   EUCTR2020-001542-19-FR   France
TC-MSC
   King's College London
      2015   Phase 1;Phase 2   EUCTR2014-004500-30-GB   United Kingdom
      2012   Phase 1;Phase 2   EUCTR2012-001394-87-GB   United Kingdom
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands
TCP-25 GEL
   Xinnate AB
      2025   Phase 2   NCT06594393   Sweden
TCP-25 GEL 0.86 MG/ML
   Xinnate AB
      2022   Phase 1   NCT05378997   Sweden
TCP-25 GEL 2.9 MG/ML
   Xinnate AB
      2022   Phase 1   NCT05378997   Sweden
TCP-25 GEL 8.6 MG/ML
   Xinnate AB
      2022   Phase 1   NCT05378997   Sweden
Tetracyclin
   Rambam Health Care Campus
      2006   Phase 4   NCT00336154   Israel
THC
   University Medical Center Groningen
      -   Phase 2   EUCTR2021-000103-20-NL   Netherlands
Thymoglobulin
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
Thymoglobuline
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands
Thymosin beta 4
   RegeneRx Biopharmaceuticals, Inc.
      2006   Phase 2   NCT00311766   United States
Tolasure topical GEL
   BioMendics, LLC
      2022   Phase 1   NCT05062070   United States
Topical beremagene geperpavec
   Krystal Biotech, Inc.
      2021   Phase 3   NCT04917874   United States
      2018   Phase 1/Phase 2   NCT03536143   United States
Topical BPM31510 3.0% cream
   Shasa Hu
      2016   Phase 1   NCT02793960   United States
Topical opiod
   Institute of Child Health
      2005   Phase 4   NCT00231517   United Kingdom
Total body irradiation
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States
      2010   Phase 1/Phase 2   NCT01033552   United States
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with A COL17a1-encoding retroviral vector
   Holostem Terapie Avanzate s.r.l.
      2017   Phase 1;Phase 2   EUCTR2016-000095-17-AT   Austria
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with A COL7a1-encoding retroviral vector
   Holostem Terapie Avanzate s.r.l.
      2016   Phase 1;Phase 2   EUCTR2015-004592-74-AT   Austria
Transplantation
   Holostem s.r.l.
      2022   Phase 2/Phase 3   NCT05111600   France;Germany;Italy
Trimethoprim
   The Hospital for Sick Children
      2006   Phase 2   NCT00380640   Canada
Triterpene DRY extract from birch cork
   Birken GmbH
      2010   -   EUCTR2010-019945-24-DE   Germany
Unavailable
   ProQR Therapeutics
      -   Phase 1;Phase 2   EUCTR2017-004806-17-FR   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
   ProQR Theraputics
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-ES   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States
   Wings Therapeutics Inc.
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-GB   Czech Republic;France;Germany;Spain;United Kingdom;United States
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-DE   Czech Republic;France;Germany;Spain;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2017-004806-17-CZ   Czech Republic;France;Germany;Spain;United Kingdom;United States
Vehicle
   Premier Specialists, Australia
      2016   Phase 2   NCT03016715   Australia
   Scioderm, Inc.
      2014   Phase 2   NCT02014376   United States
   Stanford University
      2016   Phase 2   NCT02960997   United States
   TWi Biotechnology, Inc.
      2024   Phase 2/Phase 3   NCT06073132   Australia;Austria;Belgium;France;Greece;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Spain;Taiwan;United Arab Emirates;United Kingdom;United States
      2018   Phase 2   NCT03468322   Taiwan
   Xinnate AB
      2025   Phase 2   NCT06594393   Sweden
Vehicle control
   Anterogen Co., Ltd.
      2023   Phase 2   NCT05157958   United States
Vehicle cream
   InMed Pharmaceuticals Inc.
      2021   Phase 2   NCT04908215   Austria;France;Germany;Greece;Israel;Italy
Vehicle topical GEL
   BioMendics, LLC
      2022   Phase 1   NCT05062070   United States
VPD-737
   Jean Yuh Tang
      2016   Phase 2   NCT02654483   United States
Wharton’S jelly derived mesenchymal stem cells
   Medical University of Warsaw
      2020   Phase 1;Phase 2   EUCTR2018-003890-91-PL   Poland
Zorblisa
   Scioderm INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-002288-14-BE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, An Amicus Therapeutics Company
      2016   Phase 3   EUCTR2014-002288-14-LT   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002288-14-PL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002288-14-DE   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-NL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-GB   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC
      2016   Phase 3   EUCTR2014-005679-96-ES   Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-NL   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-GB   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-005679-96-LT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005679-96-DE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2014-005679-96-PL   Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
   Scioderm, INC.
      2016   Phase 3   EUCTR2014-002288-14-ES   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2014-002288-14-IT   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States